展望2025年，华源证券认为医药板块已经具备多方面的积极发展因素，基本完成了新旧增长动能转换 （创新替代仿制，出海能力提升），具体来看，1）国内创新产业（300832）已具规模，一批药企的创 新布局迎来收获，恒瑞医药、翰森制药、科伦药业等传统pharma已完成创新的华丽转身；2）出海能力 持续提升，创新药械的licenseout频频出现，中国企业已成为全球MNC非常重视的创新转换来源。 | | 0.364 -0.004 -1.09% | | | 生物医药ETF | क्रेन 159859 | | --- | --- | --- | --- | --- | --- | | | SZSE CNY 11:15:06 交易中 | | | | 通融/ ● 十 | | 净值走势 | | 天 国正生物医药ETF | 文由 | 0.83% 120日 | -3.19% | | 三元 | 28 29% -- | 564750 | 5日 | 1.96% 250日 | 1.68% | | 元 | 0.368 | 95307 | 20日 | 3.12% 52周同 | 0.45 | | | 0.367 | 68114 | 60日 | ...

Group 1 - The Hong Kong innovative drug sector has experienced a decline, with notable drops in stock prices for several companies [1] - Biontech (06955.HK) fell over 6%, while Zai Lab (09688.HK) decreased nearly 4% [1] - Other companies such as CSPC Pharmaceutical (01093.HK), BeiGene (06160.HK), and Hansoh Pharmaceutical (03692.HK) also saw declines, with CSPC dropping over 3% [1]

Investment Rating - The report assigns a "Buy" rating to Hansoh Pharma with a 12-month price target of HK$22.71, indicating a downside potential of 20.6% from the current price of HK$28.60 [8][9]. Core Insights - Management emphasizes encouraging progress in ex-China development for out-licensed assets, including B7H3 ADC, B7H4 ADC, and oral GLP-1, with a reiterated product sales guidance of double-digit growth in 2025 [1][2]. - The key product Ameile is projected to achieve peak sales of Rmb8 billion, with additional upside potential from combination therapies [1][3]. - The company anticipates deal-making opportunities from early-stage ADCs and next-generation disease modifiers for immunology diseases [1][7]. Summary by Sections Ex-China Development Progress - HS-20093 (B7H3 ADC) has received two breakthrough designations from the FDA for SCLC and osteosarcoma, with GSK planning pivotal studies by Q4 2025 [2]. - HS-20089 (B7H4 ADC) is set to commence pivotal trials in 2026 for gynecological cancers [2]. - HS-10535 (oral GLP-1) is expected to enter phase 1 trials in 2025, targeting multiple cardiovascular and metabolic diseases [2]. - HS-20094 (GLP-1/GIP) will focus on weight reduction strategies in combination with Regeneron's internal pipeline assets [2]. Sales Growth and Commercialization - Management guides for double-digit sales growth in 2025, driven by innovative drugs, particularly Ameile, which has a revised sales target of Rmb6 billion for 2025 [3][6]. - The potential for collaboration income is highlighted as a sustainable revenue driver, supported by a growing R&D pipeline with 8-10 new INDs each year [6]. Licensing and Deal-Making Opportunities - Potential licensing-out opportunities include early-stage pre-clinical assets and several ADCs that have entered clinical stages [7]. - Specific assets with deal-making potential include HS-20122 (EGFR/cMET ADC), HS-10370 (KRAS G12D), and others targeting immunology diseases [7].

在今年科技、创新药等行情的带动下，南向资金持续加仓港股市场。 据Wind数据，今年以来，南向资金累计净流入港股市场金额超7100亿港元，远超往年同期，同时接近2024年历史最高纪录的88.83%。与此同时，南向资金在港 股市场的成交占比也在不断提升。 受访人士认为，内地资金持续关注并不断买入，表明内地投资者看到了港股市场潜在收益机会。部分港股股票估值较低、股息率较高，投资价值显著。同时，港股 市场的稀缺资产包括互联网、新消费、创新药等板块走强，也吸引了内地资金关注。 净流入超7100亿港元 今年年初以来，在DeepSeek引领中国资产重估叙事的大背景下，港股市场大幅走高。行情数据显示，截至6月25日，恒生指数年度涨幅达22.01%，恒生科技指数 年度涨幅为19.94%，市场表现在全球主要股指中排名靠前。 在此背景下，今年港股市场牛股频出，不少投资者直呼："港股或已进入牛市阶段"。Wind数据显示，在恒生指数成份股中，周大福年度涨幅超90%，翰森制药、 石药集团、小米集团等年度涨幅超60%，网易、京东健康、比亚迪股份、香港交易所等多股年度涨幅在40%以上。 内地资金定价权不断提升 南向资金的持续流入，不仅为港股 ...

Core Viewpoint - The healthcare sector is experiencing positive momentum driven by favorable policy signals and strong performance of the Hang Seng Healthcare Index and related ETFs [2][3]. Group 1: Market Performance - As of June 25, 2025, the Hang Seng Healthcare Index (HSHCI) rose by 1.37%, with notable increases in stocks such as Cloudmed (01952) up 4.52% and JD Health (06618) up 3.16% [1]. - The Hang Seng Healthcare ETF (513060) also saw a rise of 1.58%, marking its fourth consecutive increase, with a latest price of 0.58 yuan [1]. - The ETF recorded a turnover of 3.26 billion yuan, with a turnover rate of 3.98% during the trading session [1]. Group 2: Policy and Industry Insights - Recent policies from the National Medical Products Administration (NMPA) aim to streamline clinical trial approval processes, potentially reducing the time and costs associated with drug development [2]. - The China Drug Evaluation (CDE) reported a steady increase in clinical trials in oncology and autoimmune fields, indicating a growing demand for innovative drug companies and the CXO industry [2]. - The China Securities Regulatory Commission (CSRC) has introduced new listing standards for the ChiNext board, enhancing financing opportunities for unprofitable biotech companies [2]. Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF has seen a net value increase of 17.35% over the past two years, with a maximum monthly return of 28.34% since inception [3]. - The ETF's Sharpe ratio for the past year is reported at 1.66, indicating strong risk-adjusted returns [3]. - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [4]. Group 4: Valuation and Holdings - The Hang Seng Healthcare Index's latest price-to-earnings ratio (PE-TTM) stands at 27.44, which is below the historical average, suggesting a potentially undervalued market [4]. - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.34% of the index, with notable companies including Innovent Biologics (01801) and BeiGene (06160) [4].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 3.4% to 955.16 points, with a trading volume of 16.275 billion yuan [1] - The index has shown significant growth, increasing by 15.52% over the past month, 30.95% over the past three months, and 58.83% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (10.14%), BeiGene (9.67%), WuXi Biologics (9.53%), and others, indicating a concentration in leading firms within the innovative drug sector [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation from this market [1] - The industry composition of the index shows that drug formulations account for 42.00%, other biopharmaceuticals for 38.03%, pharmaceutical and biotechnology services for 19.53%, and vaccines for 0.44% [2] Group 3 - The index undergoes adjustments every six months, specifically on the second Friday of June and December, with weight factors adjusted accordingly [2] - In special circumstances, the index may be adjusted temporarily, such as when a sample company is delisted or undergoes mergers or acquisitions [2] - Changes in the Hong Kong Stock Connect eligibility may also lead to adjustments in the index samples [2]

金融界6月24日消息，上证指数低开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1513.97点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨15.00%，近三个月上涨27.95%，年至今上 涨60.32%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。当港股通范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通生物科技主 ...

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1]. Group 1: Fund Performance - As of June 24, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.25% and a trading volume of 2.373 billion yuan [1]. - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - The latest share count reached 1.478 billion, with a total fund size of 2.217 billion yuan as of June 23, reflecting a 273.92% increase in shares and a 486.71% increase in size since December 31, 2024 [1]. Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 38.434 billion yuan, averaging 1.922 billion yuan per day [1]. - Year-to-date, the ETF has seen a total trading amount of 79.325 billion yuan over 113 trading days, averaging 0.702 billion yuan per day [1]. Group 3: Fund Management - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 49.94% during the management period [1]. Group 4: Top Holdings - The ETF's top holdings include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others, with significant market values attributed to each [2].

Group 1 - The Hong Kong stock market is experiencing a collective rise, with the Hong Kong Stock Connect Innovative Drug ETF (159570) surging over 2% and achieving a trading volume exceeding 1.4 billion yuan [1] - As of 10:25, most constituent stocks of the Hong Kong Stock Connect Innovative Drug ETF (159570) are performing well, with Rongchang Bio rising over 6% and several other companies like CSPC Pharmaceutical, WuXi Biologics, and BeiGene increasing by over 2% [3] - Recent policies have provided support for innovative drugs and medical devices, including discussions on the adjustment of the national medical insurance drug list and optimization of clinical trial approvals [4] Group 2 - The pharmaceutical and biotechnology sector experienced significant declines last week, but the innovative drug sector has shown strong performance year-to-date, indicating a potential for medium to long-term investment opportunities despite short-term adjustments [5] - The China Securities Regulatory Commission has proposed measures to expedite the review and approval process for innovative drug clinical trials, aiming to encourage the development and market entry of innovative drugs [5] - The 2025 mid-term investment strategy emphasizes the importance of both domestic stability and international expansion, highlighting China's competitive advantages in population, manufacturing, and innovation capabilities [6][8] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a strong focus on the innovative drug industry, with nearly 72% of its top ten holdings in leading companies [8] - The ETF is characterized by a high concentration in innovative drugs, with an 85% weight in this category, and is currently undervalued compared to historical price-to-sales ratios [8] - The ETF allows for T+0 trading and is positioned as a medium-risk investment suitable for balanced investors [8]

Core Insights - Chinese innovative pharmaceutical companies are increasingly engaging in large-scale business development (BD) transactions, signaling a shift from being "followers" to "participants" and "contributors" in the global pharmaceutical landscape [1][6][10] Group 1: Major BD Transactions - Recently, major BD deals have been reported, including a $60 billion deal by 3SBio and a $53.3 billion strategic collaboration between CSPC and AstraZeneca [1][3] - In January, Innovent Biologics licensed its DLL3 ADC to Roche for $800 million upfront and potential milestone payments up to $1 billion [1][2] - In March, HAPO announced a global strategic partnership with AstraZeneca, receiving $175 million upfront and potential milestone payments up to $4.4 billion [2][3] Group 2: Market Trends and Growth - The total value of BD transactions for Chinese innovative drugs is projected to reach $52.3 billion in 2024, with an upfront payment of $4.1 billion, both setting historical records [3][5] - As of May 27, 2024, the total value of BD transactions for Chinese innovative drugs has already reached $45.5 billion, indicating a strong growth trajectory [3][5] Group 3: Policy and Regulatory Support - The Chinese government has implemented a series of reforms to support innovative drug development, including a significant reduction in drug approval times from an average of 3 years to 60 days [6][7] - The recent proposal to further reduce clinical trial approval times to 30 working days aims to enhance the efficiency of drug development [7][8] Group 4: Competitive Advantages - Chinese innovative drugs are becoming increasingly attractive to multinational pharmaceutical companies due to their cost-effectiveness and faster development timelines [10][11] - The average R&D cost for innovative drugs in China is significantly lower than in the U.S., with estimates suggesting costs are 20% to 30% of those in the U.S. [11][12] Group 5: Industry Positioning - China has emerged as a leader in the global pharmaceutical innovation landscape, with the number of innovative drugs entering clinical trials surpassing that of the U.S. [8][9] - The number of innovative drugs approved in China has increased dramatically, from 3 in 2015 to 39 in 2024, marking a twelvefold increase [7][8]